Addex Therapeutics: Creating Novel Small Molecule Drugs for Patients with CNS Diseases
Addex Therapeutics, a Geneva-based biotech, develops novel orally available small molecule drugs for CNS diseases like Parkinson’s and Alzheimer’s, and has accelerated its R&D innovation by overcoming challenges in data management through adopting the Dotmatics platform, which modernized their workflows, centralized data, and significantly saved scientists’ time in data analysis.
Addex Therapeutics: Creating Novel Small Molecule Drugs for Patients with Central Nervous System Diseases
Addex Therapeutics
Press O for more options
Click for sound
1:08
Addex Therapeutics, a biotech headquartered in Geneva, Switzerland, is developing novel, orally available small molecule drugs to address the unmet needs of patients with neurological disorders, such as Parkinson’s, epilepsy, Alzheimer’s, PTSD, depression, neurodegenerative conditions, and other central nervous system (CNS) diseases.
In order to quickly deliver such novel treatment options to patients with CNS diseases, the R&D teams at Addex must be nimble, data-driven, and collaborative, but doing such can be challenging when facing complex workflows, huge volumes and varieties of R&D data, and occasional staff departures.
Challenge: Accelerate Innovation via Better R&D Data Management
-
Outdated and Unsupported Platform
-
Poor Data Management
-
Time Wasted Analyzing Data
Solution: Centralizing and Analyzing Data with Dotmatics Platform
-
Modernized Platform
-
Easy and Manageable Data Flows
-
Substantial Time Savings
“One of the biggest, unexpected consequences we’ve seen from integrating Dotmatics is that it saves scientists hours of time spent in analyzing data compared to our previous solution.” - Eric Gaillard, Head of IT and Facility